Q3 EPS Estimate for Denali Therapeutics Increased by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Tuesday, April 7th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.73) per share for the quarter, up from their prior estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($2.72) EPS, FY2029 earnings at ($1.93) EPS and FY2030 earnings at ($0.36) EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the company earned ($0.67) EPS.

Other research analysts also recently issued reports about the company. Stifel Nicolaus increased their target price on Denali Therapeutics from $34.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wolfe Research started coverage on Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Wedbush lowered their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. Finally, Morgan Stanley raised their price target on Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.00.

Denali Therapeutics Stock Up 1.1%

NASDAQ DNLI opened at $19.62 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The company has a market capitalization of $3.11 billion, a P/E ratio of -6.61 and a beta of 1.10. Denali Therapeutics has a one year low of $10.80 and a one year high of $23.77. The stock has a 50 day moving average price of $20.40 and a 200-day moving average price of $18.18.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNLI. Norges Bank purchased a new stake in Denali Therapeutics in the fourth quarter worth $84,525,000. Holocene Advisors LP increased its stake in Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after purchasing an additional 2,732,540 shares during the period. Goldman Sachs Group Inc. increased its stake in Denali Therapeutics by 77.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after purchasing an additional 1,672,098 shares during the period. Temasek Holdings Private Ltd increased its stake in Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after purchasing an additional 1,657,142 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its stake in Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.